Skip to main content

Table 3 Univariate and multivariate analyses for overall survival in women with stage III mucinous ovarian carcinoma (n = 81)

From: Comparison of stage III mucinous and serous ovarian cancer: a case-control study

  Univariate analysis OSa
N of events (%)
p Multivariate analysis
HR CI 95% p
Age, y
  < 54 17/39 (52.2%) 0.126    
  ≥ 54 24/42 (38.1%)    
Menopausal Status
 Premenopausal 15/32 (49%) 0.49    
 Postmenopausal 26/49 (42%)    
Ca-125(IU/ml)
  < 126 19/40 (49.2%) 0.42    
  ≥ 126 22/41 (40.4%)    
Grade
 1 16/29 (36%) 0.98    
 2–3 25/52 (48%)    
Ascites
 Present 24/42 (37.4%) 0.174    
 Absent 17/39 (52.4%)    
LN metastases
 Present 13/21 (27.9%) 0.433    
 Absent 28/60 (50.4%)    
Peritoneal cytology
 Positive 35/61 (36.8%) 0.092    
 Negative 6/20 (67.7%)    
Appendiceal Involvement
 Present 18/29 (30.9%) 0.180    
 Absent 23/52 (51.9%)    
Omental Involvement
 Present 35/61 (37%) 0.008    
 Absent 6/20 (68.4%)    
Stage
 IIIA1 2/13 (83.9%) 0.002    
 IIIA2, IIIB, IIIC 39/68 (37%)    
Debulking
 Maximal 6/27 (74.3%) < 0.001 0.37 0.16–0.86 0.021
 Optimal 35/54 (30.1%)
  1. a:5-year overall survival rate
  2. Abbreviations: MOC Mucinous Ovarian Carcinoma, OS Overall Survival, LN Lymph node, HR Hazard ratio, CI Confidence interval, y Years